IMMUNOHISTOCHEMICAL EXPRESSION OF CTLA-4 IN CERVICAL CARCINOMA.

Document Type : Preliminary preprint short reports of original research

Authors

1 Department of Pathology,* Faculty of Medicine, Alexandria University

2 Department of pathology, Faculty of Medicine,University of Alexandria.

3 Department of Pathology, Faculty of Medicine, University of Alexandria.

Abstract

Cervical cancer is the fourth most common cancer in females, accounting for 6.5% of total cancer incidence in women. It is also considered the most common gynecological cancer. The main cause of cervical cancer is a persistent infection with high-risk types of the human papillomavirus (HPV). P16 is considered a surrogate maker for high-risk human papillomavirus (hrHPV) infection. The standard management of cervical cancer, based on stage, histology, and patient-specific factors, encompasses a variety of strategies, including surgical interventions, radiotherapy, chemotherapy, and novel immunotherapies. Immune checkpoints including CTLA-4 are important molecules for immune system regulation & prevention of autoimmune diseases, but tumors can exploit them to evade anti-tumor immunity. CTLA-4 antibody can induce anti-tumor immunity, effectively amplifying T cells and enhancing the anti-tumor response.
AIM:
The aim of this study was to assess the immunohistochemical expression of CTLA-4 in cervical carcinoma in relation to histologic type, grade, stage and other clinicopathological parameters.

Keywords

ALEXMED ePosters
Volume 6, Issue 4
September 2024
Pages 74-75

Files

Share

How to cite

Statistics